Dihydroartemisinic acidCAS# 85031-59-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 85031-59-0 | SDF | Download SDF |
| PubChem ID | 11020893 | Appearance | Powder |
| Formula | C15H24O2 | M.Wt | 236.35 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R)-2-[(1R,4R,4aS,8aS)-4,7-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl]propanoic acid | ||
| SMILES | CC1CCC(C2C1CCC(=C2)C)C(C)C(=O)O | ||
| Standard InChIKey | JYGAZEJXUVDYHI-DGTMBMJNSA-N | ||
| Standard InChI | InChI=1S/C15H24O2/c1-9-4-6-12-10(2)5-7-13(14(12)8-9)11(3)15(16)17/h8,10-14H,4-7H2,1-3H3,(H,16,17)/t10-,11-,12+,13+,14+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Dihydroartemisinic acid is a precursor to the antimalarial agent artemisinin. |
Dihydroartemisinic acid Dilution Calculator
Dihydroartemisinic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.231 mL | 21.1551 mL | 42.3101 mL | 84.6203 mL | 105.7753 mL |
| 5 mM | 0.8462 mL | 4.231 mL | 8.462 mL | 16.9241 mL | 21.1551 mL |
| 10 mM | 0.4231 mL | 2.1155 mL | 4.231 mL | 8.462 mL | 10.5775 mL |
| 50 mM | 0.0846 mL | 0.4231 mL | 0.8462 mL | 1.6924 mL | 2.1155 mL |
| 100 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 0.8462 mL | 1.0578 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Acetyl Perisesaccharide C
Catalog No.:BCN8666
CAS No.:110764-09-5
- Z-VDVAD-FMK
Catalog No.:BCC1138
CAS No.:N/A
- Isoboonein
Catalog No.:BCN4545
CAS No.:99946-04-0
- Bullatantriol
Catalog No.:BCN4543
CAS No.:99933-32-1
- 3-(3,4-Dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide
Catalog No.:BCN8535
CAS No.:99933-30-9
- RGD (Arg-Gly-Asp) Peptides
Catalog No.:BCC5349
CAS No.:99896-85-2
- Isoboonein acetate
Catalog No.:BCN4542
CAS No.:99891-77-7
- Kaempferol 3-O-arabinoside
Catalog No.:BCN4541
CAS No.:99882-10-7
- Droxinostat
Catalog No.:BCC2157
CAS No.:99873-43-5
- Rotigotine
Catalog No.:BCC1907
CAS No.:99755-59-6
- Scholaricine
Catalog No.:BCN4539
CAS No.:99694-90-3
- 14-Benzoylneoline
Catalog No.:BCN6493
CAS No.:99633-05-3
- Rhein-8-glucoside
Catalog No.:BCN8548
CAS No.:34298-86-7
- Cistanoside F
Catalog No.:BCN8549
CAS No.:97411-47-7
- Vinaginsenoside R3
Catalog No.:BCN8550
CAS No.:156012-92-9
- 28-Demethyl-beta-amyrone
Catalog No.:BCN8551
CAS No.:73493-60-4
- Ilexsaponin B2
Catalog No.:BCN8552
CAS No.:108906-69-0
- Trans sodium crocetinate
Catalog No.:BCN8553
CAS No.:591230-99-8
- Panasenoside
Catalog No.:BCN8554
CAS No.:31512-06-8
- Ginsenoside Ra2
Catalog No.:BCN8555
CAS No.:83459-42-1
- Uvarigranol B
Catalog No.:BCN8556
CAS No.:164204-79-9
- Rupestonic acid
Catalog No.:BCN8557
CAS No.:115473-63-7
- Dihydropalmatine
Catalog No.:BCN8558
CAS No.:26067-60-7
- Anemarrhenasaponin I
Catalog No.:BCN8559
CAS No.:163047-21-0
Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin.[Pubmed:22247290]
Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):E111-8.
Malaria, caused by Plasmodium sp, results in almost one million deaths and over 200 million new infections annually. The World Health Organization has recommended that artemisinin-based combination therapies be used for treatment of malaria. Artemisinin is a sesquiterpene lactone isolated from the plant Artemisia annua. However, the supply and price of artemisinin fluctuate greatly, and an alternative production method would be valuable to increase availability. We describe progress toward the goal of developing a supply of semisynthetic artemisinin based on production of the artemisinin precursor amorpha-4,11-diene by fermentation from engineered Saccharomyces cerevisiae, and its chemical conversion to Dihydroartemisinic acid, which can be subsequently converted to artemisinin. Previous efforts to produce artemisinin precursors used S. cerevisiae S288C overexpressing selected genes of the mevalonate pathway [Ro et al. (2006) Nature 440:940-943]. We have now overexpressed every enzyme of the mevalonate pathway to ERG20 in S. cerevisiae CEN.PK2, and compared production to CEN.PK2 engineered identically to the previously engineered S288C strain. Overexpressing every enzyme of the mevalonate pathway doubled artemisinic acid production, however, amorpha-4,11-diene production was 10-fold higher than artemisinic acid. We therefore focused on amorpha-4,11-diene production. Development of fermentation processes for the reengineered CEN.PK2 amorpha-4,11-diene strain led to production of > 40 g/L product. A chemical process was developed to convert amorpha-4,11-diene to Dihydroartemisinic acid, which could subsequently be converted to artemisinin. The strains and procedures described represent a complete process for production of semisynthetic artemisinin.
